Stockreport

First-in-class cholesterol-lowering treatment NILEMDO®? and its combination with ezetimibe, NUSTENDI®?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk [Yahoo! F...

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF update approval from the European Commission as treatments to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels This makes bemp [Read more]